Clinical Trials for HER2-Positive Breast Cancer
HER2-positive breast cancer is a subtype in which the cancer cells overexpress a protein called HER2 (human epidermal growth factor receptor 2). This overexpression drives cancer growth, but it also creates a target for highly effective therapies. HER2-targeted treatments like trastuzumab (Herceptin) have transformed outcomes for this subtype -- and they emerged from exactly the kind of clinical trial research that continues today.
If you have HER2-positive breast cancer and are facing a coverage denial or a situation where your current therapy is no longer working, clinical trials may offer access to the next generation of treatment.
According to the National Cancer Institute, approximately 15-20% of breast cancers are HER2-positive.
What Types of Trials Are Available?
HER2-targeted therapy trials are studying newer antibody-drug conjugates (ADCs), which combine a targeted antibody with a powerful chemotherapy agent delivered directly to cancer cells. These represent one of the most active areas in breast cancer research. Combination immunotherapy trials study whether adding checkpoint inhibitors to HER2-targeted therapy improves outcomes, particularly in metastatic disease. Neoadjuvant and adjuvant trials are studying treatments given before or after surgery, respectively, with the goal of improving rates of pathologic complete response and reducing recurrence. Brain metastasis trials specifically address HER2-positive disease that has spread to the brain, which is a particular challenge in this subtype. Several trials are enrolling people with active brain metastases. Biomarker-driven trials study whether specific characteristics of HER2-positive tumors predict who will respond best to which treatment.Search ClinicalTrials.gov for currently recruiting trials.
Am I Eligible?
Eligibility for HER2-positive breast cancer trials typically depends on:
- Confirmed HER2 overexpression or amplification (IHC 3+ or FISH amplified)
- Disease stage (early, locally advanced, or metastatic)
- Prior treatment history in HER2-targeted therapy
- Performance status and organ function (kidney, liver, heart)
- Brain metastasis status (presence or absence, stable vs. active)
- Hormone receptor status (ER+/PR+, or triple-negative)
Your oncologist will be able to map your specific profile to current trial eligibility criteria. Talk to your doctor before making any decisions about your treatment.
What If My Insurance Denied My Medication?
HER2-targeted therapies can be expensive, and insurance denials do happen -- particularly for newer agents or combinations not yet standard on a plan's formulary. If your oncologist has prescribed a HER2-targeted therapy and your insurer has denied it, you have the right to appeal.
Ask your oncologist whether your hospital or practice is running any HER2-positive trials. NCI-designated breast cancer programs often have active trials that provide access to newer HER2-targeted agents that may not yet be covered by insurance.
Pursuing a trial does not mean giving up your appeal. Both can happen at the same time.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Are clinical trials for HER2-positive breast cancer free?
In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.
How do I find HER2-positive breast cancer trials near me?
The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.
Can I join a trial after being denied Herceptin or Enhertu?
Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Herceptin or Enhertu or similar medications.